Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00004793
Other study ID # 199/11923
Secondary ID UMMC-1354
Status Completed
Phase N/A
First received February 24, 2000
Last updated June 23, 2005
Start date June 1995

Study information

Verified date December 2001
Source Office of Rare Diseases (ORD)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

OBJECTIVES: I. Evaluate the effect of bromocriptine on luteinizing hormone (LH) secretion by suppression of prolactin and stimulation of dopaminergic receptors in early pubertal boys and girls.

II. Evaluate the effect of baclofen on LH secretion by stimulation of gamma-aminobutyric acid receptors in early pubertal boys and girls.


Description:

PROTOCOL OUTLINE:

Participants receive bromocriptine or baclofen followed by nocturnal measurements of luteinizing hormone, growth hormone, and sex steroids. Pituitary reserve is evaluated with the administration of gonadotropin-releasing hormone, and in children undergoing assessment of short stature, standard provocative stimuli.


Recruitment information / eligibility

Status Completed
Enrollment 4
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A to 18 Years
Eligibility - Short stature and/or constitutional growth delay

- No epilepsy or risk of epilepsy

Study Design

Primary Purpose: Screening


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
National Center for Research Resources (NCRR) University of Michigan
See also
  Status Clinical Trial Phase
Completed NCT01376921 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Spain N/A
Completed NCT01400997 - Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Czech Republic N/A
Completed NCT05244785 - Health and Nutrition Survey on Shenzhen Children
Completed NCT00097539 - A Postmarketing Surveillance Program for Nutropin, Nutropin AQ, and Protropin Phase 4
Not yet recruiting NCT04576845 - The Effect of Early Childhood Cow's Milk Allergy Elimination Diet on Eating Behaviors, Nutrition, and Growth Status
Not yet recruiting NCT05056285 - Pattern of Growth and Characteristics of Down Syndrome Pediatrics Patients
Completed NCT01263457 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in the UK
Terminated NCT00330668 - Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency Phase 3
Completed NCT00378859 - The Effect of Milk and Meat on IGFs in Prepubertal Boys N/A
Not yet recruiting NCT05577130 - Growth Pattern and Characteristics of Cardiac Pediatric Patients
Recruiting NCT05033119 - PROSA: Prolactin, Sex Hormones, Growth and Metabolic Biomarkers in Children and Adolescents on Antipsychotics
Completed NCT01402999 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Hungary N/A
Completed NCT01267526 - A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment N/A
Completed NCT00139451 - Nutrients and Hormones: Effects in Boys With Disordered Growth Phase 2
Terminated NCT03274973 - Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome
Completed NCT02015286 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East N/A
Completed NCT01582334 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Argentina N/A
Completed NCT01439061 - To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Italy N/A
Completed NCT00125164 - Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency Phase 3
Completed NCT00174408 - Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age Phase 3